NeoLumina BioScience to Initiate Strategic Collaboration for Novel Psilocin Delivery System to Advance Mental Health Treatment
VANCOUVER, BRITISH COLUMBIA / July 17, 2025/ NeoLumina BioScience Inc., a pioneering clinical-stage biopharmaceutical company dedicated to developing breakthrough treatments for mental health disorders using psychedelics, announces the commencement toward a significant collaboration with a leading global contract design and manufacturing organization. This partnership aims to leverage proprietary technology to develop a first-in-class psilocin delivery product capable of providing consistent, pre-determined doses of the active compound derived from psilocybin.
This innovative product is envisioned to serve a broad spectrum of mental health conditions, offering a novel, patentable solution that could revolutionize the administration of psychedelic-based therapies. To fund the initial phase of this collaboration, NeoLumina is seeking a seed-round investment of $5 million, which will facilitate the execution of the agreement and accelerate product development.
“This collaboration has the potential to generate substantial additional value for our company,” said Dr. Gaetano Morello, ND., CEO of NeoLumina. “By creating a superior, patentable product, we open new avenues for product development and licensing across multiple mental health conditions, ultimately expanding our impact in the field.”
In addition to this partnership, NeoLumina is actively preparing to seek FDA approval to start a Phase 2 clinical trial of its lead psilocybin-based product candidate, a proprietary technology with numerous issued patents, aimed at treating binge eating disorder. The company’s robust intellectual property portfolio and innovative approach position it at the forefront of psychedelics-based mental health therapeutics.
Jeremy Baker, Chief Business Officer of NeoLumina, added, “Our collaborator’s decision to move forward with us largely reflects the strength of our high-caliber management team and distinguished advisory board, which includes experts such as Dr. Mark Gold, MD, Distinguished Professor of Psychiatry at the University of Florida; Dr. Wendy Oliver-Pyatt, MD, Director of the International Association of Eating Disorder Professionals; and Dr. Michael Murray, ND, a globally recognized authority on natural medicine.”
NeoLumina remains committed to advancing therapies that can improve patient outcomes significantly and address unmet needs in mental health care. For further information, please contact:
Jeremy Baker – NeoLumina Bioscience Inc
+1 833-303-1883 email us here
Visit us on social media:
Facebook / Twitter / LinkedIn / Instagram
About NeoLumina BioScience Inc.
NeoLumina BioScience is dedicated to pioneering innovative psychedelic-based treatments for mental health disorders. Its mission is to leverage cutting-edge scientific research and proprietary technology to develop novel, effective, and safe therapies that transform lives worldwide.
Forward Looking Statements
To the extent statements contained in this news release are not descriptions of historical facts regarding NeoLumina Bioscience Inc. they should be considered “forward-looking statements,” as described in the private securities litigation reform act of 1995, that reflect management’s current beliefs and expectations. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “hope,” “hypothesis,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “will,” “would,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this news release include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) the anticipated timing of clinical data availability; (v) our ability to meet our milestones; and (vi) our expectations regarding our ability to obtain and maintain intellectual property protection. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements.
